Filing Details

Accession Number:
0001656472-21-000027
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-04 17:39:44
Reporting Period:
2021-03-02
Accepted Time:
2021-03-04 17:39:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1656472 Cronos Group Inc. CRON Medicinal Chemicals & Botanical Products (2833) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797199 Ryan Michael Gorenstein 111 Peter Street, Suite 300
Toronto A6 M5V 2H1
Executive Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2021-03-02 487,500 $0.39 4,999,796 No 4 M Direct
Common Shares Disposition 2021-03-02 143,485 $11.00 4,856,311 No 4 F Direct
Common Shares Acquisiton 2021-03-02 3,990,221 $0.19 8,846,532 No 4 M Direct
Common Shares Disposition 2021-03-02 69,981 $11.00 8,776,551 No 4 F Direct
Common Shares Disposition 2021-03-02 230,000 $11.05 8,546,551 No 4 S Direct
Common Shares Disposition 2021-03-03 114,015 $10.39 8,432,536 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares COMMON SHARE OPTION (right to buy) Disposition 2021-03-02 487,500 $0.00 487,500 $0.39
Common Shares WARRANTS Disposition 2021-03-02 3,990,221 $0.00 3,990,221 $0.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-08-05 No 4 M Direct
0 2021-05-27 No 4 M Direct
Footnotes
  1. The price reported was converted from the Canadian exercise price of C$0.50 to U.S. dollars using an exchange rate of C$1.00 to US$0.7875 as reported by Bloomberg as of March 1, 2021.
  2. Cronos Group Inc. (the "Company") withheld 143,485 common shares underlying the options for payment of the exercise price and to cover applicable withholding taxes, using the closing price of the Company's common shares on March 1, 2021 of C$13.97 as reported on the Toronto Stock Exchange.
  3. The price reported is in U.S. dollars based on the exchange rate of C$1.00 to US$0.7875 as reported by Bloomberg as of March 1, 2021.
  4. The price reported was converted from the Canadian exercise price of C$0.245 to U.S. dollars using an exchange rate of C$1.00 to US$0.7875 as reported by Bloomberg as of March 1, 2021.
  5. On March 2, 2021, the reporting person exercised warrants to purchase 3,990,221 common shares of the Company for C$0.245 per common share. The reporting person paid the exercise price on a cashless basis, resulting in the Company's withholding of 69,981 common shares to pay the exercise price and issuing to the reporting person the remaining 3,920,240 common shares.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.715 to $11.37, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) and footnote (7) to this Form 4.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.23 to $10.5901, inclusive.
  8. The options were granted August 5, 2016 and vested in monthly installments over a four-year period.
  9. The warrants were issued between May 16, 2016 and August 12, 2016 and were immediately exercisable.